Drug profile · INN
tofacitinib citrate
XELJANZ INITIAL APPROVAL
- US status
- approved
- Patents linked
- 2
- News articles
- 0
Quick answer
tofacitinib citrate (XELJANZ INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN tofacitinib citrate
Brand XELJANZ INITIAL APPROVAL
Route ORAL
Formulation TABLET, EXTENDED RELEASE
Related patents
Search patents →Frequently asked questions
What is tofacitinib citrate?
tofacitinib citrate (XELJANZ INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tofacitinib citrate?
XELJANZ INITIAL APPROVAL is a marketed brand name for tofacitinib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tofacitinib citrate?
tofacitinib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.